In addition to the more widely used acetylcholinesterase inhibitors (AChERs) and NMDA receptor antagonists, the market for AD treatments has seen significant advancements in the last five years, particularly with the introduction of additional Aβ targeting monoclonal antibodies. Here, ACHE is linked to Alzheimer disease.